QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   906.69 (+0.46%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.41 (+1.15%)
T   17.63 (+0.46%)
F   13.22 (+1.23%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.33 (-2.66%)
DIS   122.31 (+1.10%)
AMC   3.66 (-15.67%)
PFE   27.82 (+0.14%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   906.69 (+0.46%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.41 (+1.15%)
T   17.63 (+0.46%)
F   13.22 (+1.23%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.33 (-2.66%)
DIS   122.31 (+1.10%)
AMC   3.66 (-15.67%)
PFE   27.82 (+0.14%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   906.69 (+0.46%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.41 (+1.15%)
T   17.63 (+0.46%)
F   13.22 (+1.23%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.33 (-2.66%)
DIS   122.31 (+1.10%)
AMC   3.66 (-15.67%)
PFE   27.82 (+0.14%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)
QQQ   444.82 (+0.00%)
AAPL   172.00 (-0.76%)
MSFT   421.14 (-0.07%)
META   488.20 (-1.15%)
GOOGL   151.22 (+0.23%)
AMZN   180.54 (+0.39%)
TSLA   176.24 (-2.00%)
NVDA   906.69 (+0.46%)
NIO   4.51 (-3.43%)
AMD   180.55 (+0.53%)
BABA   72.41 (+1.15%)
T   17.63 (+0.46%)
F   13.22 (+1.23%)
MU   117.98 (-0.97%)
CGC   8.63 (-9.63%)
GE   175.33 (-2.66%)
DIS   122.31 (+1.10%)
AMC   3.66 (-15.67%)
PFE   27.82 (+0.14%)
PYPL   67.27 (+1.05%)
XOM   116.08 (+0.97%)

uniQure (QURE) Stock Price, News & Analysis

$5.24
-0.17 (-3.14%)
(As of 03:05 PM ET)
Today's Range
$5.16
$5.40
50-Day Range
$4.82
$6.75
52-Week Range
$4.76
$22.48
Volume
473,138 shs
Average Volume
1.07 million shs
Market Capitalization
$250.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$32.00

uniQure MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
513.0% Upside
$32.00 Price Target
Short Interest
Bearish
12.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$339,845 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.49) to ($4.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

604th out of 938 stocks

Pharmaceutical Preparations Industry

279th out of 433 stocks

QURE stock logo

About uniQure Stock (NASDAQ:QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE Stock Price History

QURE Stock News Headlines

uniQure: The AMT-130 Readout
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
[BUY ALERT] Our #1 A.I. Stock for March
It's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.
5 unique date ideas in NW Arkansas - Axios
Amazon has a unique inflation problem - Reuters
See More Headlines
Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:QURE
Employees
480
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$32.00
High Stock Price Target
$56.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+506.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-308,480,000.00
Net Margins
-1,947.09%
Pretax Margin
-1,934.97%

Debt

Sales & Book Value

Annual Sales
$15.84 million
Book Value
$4.34 per share

Miscellaneous

Free Float
45,901,000
Market Cap
$252.60 million
Optionable
Optionable
Beta
0.97
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


QURE Stock Analysis - Frequently Asked Questions

Should I buy or sell uniQure stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" QURE shares.
View QURE analyst ratings
or view top-rated stocks.

What is uniQure's stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for uniQure's shares. Their QURE share price targets range from $7.00 to $56.00. On average, they anticipate the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 513.0% from the stock's current price.
View analysts price targets for QURE
or view top-rated stocks among Wall Street analysts.

How have QURE shares performed in 2024?

uniQure's stock was trading at $6.77 on January 1st, 2024. Since then, QURE shares have decreased by 22.9% and is now trading at $5.22.
View the best growth stocks for 2024 here
.

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QURE earnings forecast
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.54) by $0.01. The biotechnology company earned $6.69 million during the quarter, compared to analyst estimates of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 99.31% and a negative net margin of 1,947.09%.

What ETF holds uniQure's stock?

Global X Genomics & Biotechnology ETF holds 100,751 shares of QURE stock, representing 0.69% of its portfolio.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).

Who are uniQure's major shareholders?

uniQure's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vestal Point Capital LP (8.21%), Schroder Investment Management Group (2.60%), Vanguard Group Inc. (2.01%), Vanguard Group Inc. (2.01%), Point72 Asset Management L.P. (1.95%) and BNP Paribas Financial Markets (1.48%). Insiders that own company stock include Alexander Edward Kuta III, Christian Klemt, Leonard E Post, Matthew C Kapusta, Paula Soteropoulos, Pierre Caloz, Rachelle Suzanne Jacques, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends
.

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QURE) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners